Submitted by web@researchtop... on Mon, 05/20/2019 - 17:19

This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

The pace of oncology drug development has accelerated in recent years to previously unmatched rates. Fueled by an increased understanding of the biologic underpinnings of tumor development and growth, clinical research focused on the potential benefits of novel targeted therapeutic agents with unique mechanisms of action and safety profiles has improved outcomes in myriad large and rigorous clinical trials across many tumor types. The successes yielded by this rational approach to the design and evaluation of therapies have in turn provided oncology healthcare professionals and patients with new FDA-endorsed treatment options. Although this dynamic is evident in many areas of oncology, recent advances in the management of gynecologic cancers (ovarian, cervical and endometrial cancer) have made it particularly important in this corner of medicine. A plethora of extremely promising data sets have recently emerged, stirring significant enthusiasm for the possibility that several more novel approaches may soon become available to practicing clinicians. Existing management algorithms for these gynecologic cancers are poised for further change, and it is therefore critical that continuing education be offered to all practitioners involved in patient care.

This CME program was developed from the proceedings of a satellite symposium held during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. It features leading gynecologic cancer researchers discussing actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.


Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CME credit is no longer available for this issue

This CME activity consists of an audio component.
CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michael J Birrer, MD, PhD
Director, O’Neal Comprehensive Cancer Center
Professor of Medicine/Hematology and Oncology
Evalina B Spencer Chair in Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

No relevant conflicts of interest to disclose.

David M O’Malley, MD
Medical Director, Gynecologic Oncology
Director, Clinical Research, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James Cancer Center
Columbus, Ohio

Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GOG Foundation Inc, Janssen Biotech Inc, Myriad Genetic Laboratories Inc, Tesaro; Consulting Agreements: AbbVie Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, ImmunoGen Inc, Partnership for Health Analytic Research LLC, Tesaro; Contracted Research: Agenus Inc, Ajinomoto, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, EMD Serono Inc, Ergomed PLC, Exelixis Inc, Genentech, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Ludwig Institute for Cancer Research Ltd, Novartis, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Stemcentrx, Syneos Health, Tesaro, TRACON Pharmaceuticals Inc; Data and Safety Monitoring Board: Marker Therapeutics Inc.

Matthew A Powell, MD
Professor and Chief
Division of Gynecologic Oncology
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements and Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Tesaro.

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Tesaro; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, Novartis, Roche Laboratories Inc, Tesaro; Data and Safety Monitoring Board/Committee: Syndax Pharmaceuticals Inc, Xenetic Biosciences Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Eisai Inc, Genmab and Seattle Genetics, ImmunoGen Inc and Tesaro.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: June 2019
Expiration date: June 2020